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ABSTRACT  
Background and Aims: Poor adherence to medications is a major health concern 
especially among older subjects. To plan future studies to improve adherence, an 
epidemiological study, called “Fiesole Misurata”, was conducted. The aim of the 
present paper was to verify the representativeness of the database in evaluating the 
AntiHyperTensives (AHTs)-taking behaviour.  
Methods: Demographic records of all subjects aged ≥ 65 years (n=2,228) living in the 
community of Fiesole (Florence, Italy) was retrieved from the Registry Office of 
Fiesole Municipality. The corresponding healthcare records were obtained from 
administrative archives of the Local Health Authority (claim dataset). Moreover, a 
cohort of subjects aged ≥65 years (n=385) living in the community was screened by 
means of a multidimensional geriatric evaluation (cross-sectional dataset).  
Results: In claim dataset, biyearly prevalences of hospitalization for ischemic 
cardiomyopathy, heart failure, and stroke were 3.7%,  3.0%,  and 3.2%, respectively. In 
the cross-sectional dataset, prevalences were  11.2%, 6.7%, and 7.1%, respectively. The 
most used drugs were angiotensin-converting enzyme (ACE) inhibitors (43.6% in the 
claim dataset, 45.3% in the cross-sectional dataset) and diuretics (35.6% and 47.0%, 
respectively). Among the incident users of AHTs, 63.5% was highly adherent (≥80%) 
over the first six months of follow-up, while 14.3% and 22.2% were intermediate (40-
79%) and low (<40%) adherent. The percentage of high adherers decreased with time 
and reached 31.2% at the 24th month. 
Conclusions: These findings indicate that “Fiesole Misurata” study database can be 
used to develop future strategies aimed at improving the adherence to AHTs in older 
individuals. 
 
 
 
 
 
3 
 
INTRODUCTION 1 
Poor adherence to medications is a major health concern [1] especially among older 2 
subjects. Generally, when all drug categories are taken into account, the proportion of 3 
non-adherent older subjects varies from 40 to 75% [2]. This issue is particularly 4 
relevant for chronic asymptomatic diseases, such as hypertension, dyslipidaemias, 5 
diabetes,or other age-related disorders.  6 
In specific, most of  the fatal CardioVascular (CV) events occur in individuals 7 
aged 65 or older, in which the prevalence of hypertension is greater than in younger 8 
adults  and leads to half and approximately to two-thirds of  Coronary Heart Diseases 9 
(CHD), and cerebrovascular events, respectively [3-6]. Therefore, an inadequate Blood 10 
Pressure (BP) control could significantly increase the risk of death because of ischemic 11 
heart disease and stroke [7-9].   12 
Although data on the clinical burden of non-adherence to AntiHyperTensives 13 
(AHTs) among older individuals are scanty, prior findings raised concerns about the 14 
relevance of non-adherence to AHTs, that hampers the effectiveness of these 15 
medications. Specifically, it has been demonstrated that among middle-aged patients an 16 
high adherence to AHTs is associated with a significant decreased risk (38%) of major 17 
CV events when compared with a low adherence [10]. 18 
The basis of poor medication-taking behaviour is multifactorial, as demonstrated 19 
by the strict relationship between a greater therapeutic complexity and a low adherence 20 
to CV medications [11].  In this context, the older community-dwelling people are the 21 
best example of therapeutic complexity, given the higher number of coexistent diseases 22 
and concomitant medications as well as the co-occurrence of other conditions, such as 23 
functional and cognitive impairments, age-related physiological complications (i.e., 24 
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reduced liver and kidney function), which cannot be necessarily ascribed to a specific 1 
organic disease [12]. 2 
There are many unanswered questions on the most effective strategies for 3 
improving medications adherence in older subjects. They can be addressed with the use 4 
of electronic healthcare databases [13]. Claim repositories, which comprise all 5 
reimbursed drug prescriptions, hospital admissions diagnoses, and mortality registers 6 
can be valid tools in implementing intervention strategies. Nevertheless, claim 7 
databases are not designed for a specific research question, so certain variables (i.e. 8 
values of  BP, disability and cognitive status) are often unavailable [2, 14]. For this 9 
reason, research on antihypertensive non-adherence in the elderly, cannot be 10 
exhaustively satisfied with the use of claim database since some confounders are not 11 
measurable.  12 
To overcome this issue and with the aim to plan future studies to improve 13 
adherence, an epidemiological study, called the “Fiesole Misurata” study, was 14 
conducted in Fiesole, a small town of Tuscany, Italy, located in the hill north of  15 
Florence, and an ad hoc database was assembled. The name of the study can be 16 
translated as “Measuring Fiesole” since the database comprises several “measurements” 17 
(overall representing a multidimensional evaluation) of the population living in Fiesole, 18 
including socio-demographic and clinical information of all older (≥65 years) residents, 19 
who were retrospectively collected using claims data. In addition, a cohort of subjects 20 
underwent  a  multidimensional geriatric evaluation with the aim of estimating clinical 21 
variables (measures) which are generally unavailable in the administrative repositories.  22 
As a first step, we verified the database representativeness in evaluating the 23 
AHTs-taking behaviour: to this aim, data of the “Fiesole Misurata” study concerning 24 
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CV diseases, pharmacotherapy and geriatric assessments were compared with those 1 
from other epidemiological studies and official statistics.    2 
   3 
METHODS 4 
The target population of the “Fiesole Misurata” study database was composed of 5 
individuals aged 65 or more living in Fiesole county (Tuscany, Italy). The community 6 
living in this area is distributed in nine districts (Fiesole City, Anchetta, Caldine, 7 
Compiobbi, Ellera, Girone, Pian del Mugnone, Pian di San Bartolo, San Domenico) and 8 
counts 14,264 inhabitants over an area of 42.11 km2 (population density: 340,6 km2). 9 
Fiesole citizens have the third highest mean income (€ 17,638 per resident) of Tuscany 10 
and the 51st of Italy [15].   11 
Firstly, a list of all residents aged 65 years or more in the community of Fiesole 12 
was obtained on May 1st 2010 from the Municipality Registry Office and was merged  13 
with the healthcare records obtained from administrative archives of the Local Health 14 
Authority was performed by using the citizen’s fiscal code as unique identifier 15 
(n=2,228, the claim dataset). Any identification code was automatically converted to a 16 
unique anonymous code [16]. 17 
Afterwards, all eligible subjects (n=2,228) were contacted by phone, were 18 
informed about the study, and were asked for their participation. Three-hundred and 19 
eighty-five subjects aged 65 years or more living in the community of Fiesole city 20 
decided to participate (n=385, the cross-sectional dataset). Therefore, an appointment 21 
was scheduled for each participant and data on multidimensional geriatric assessment 22 
(including BP measurement), self-reported drug consumption, and information on 23 
socio-demographic status along with lifestyle-related features were collected.  24 
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The study was approved by the Local Ethic Committee, and all participants 1 
signed their informed consent before being interviewed or visited.  2 
 3 
Data collection 4 
Claims dataset 5 
Admission diagnoses (coded by the International Classification Disease, 9th version, 6 
Clinical Modification -ICD9CM) [17-21] and all reimbursed drug prescriptions (coded 7 
by the Anatomical Therapeutic Chemical -ATC- classification) were retrospectively 8 
obtained for the period between 1 January, 2008 and 31 July , 2010.  9 
Hospital admissions (in primary and/or secondary positions) for diabetes 10 
(ICD9CM code or antidiabetics use, ATC A10*), ischemic cardiomyopathy, heart 11 
failure, haemorrhagic and ischemic stroke, cardiac arrhythmia, were identified.  12 
All AHTs pharmacy claims related to Angiotensin-Converting Enzyme (ACE)  13 
inhibitors, angiotensin II receptor antagonist (sartans), diuretics,  DiHydroPiridine 14 
(DHP) Calcium Channel Blockers (CCBs), non-DHP CCBs, beta blockers, peripheral 15 
alpha blockers, central inhibitors and the fixed combinations (i.e., ACE inhibitors or 16 
sartans or beta blockers with diuretics) were extracted.  Furthermore, antithrombotics, 17 
antiarrhythmics, lipid lowering drugs and digitalis, as well as the number of ATC 18 
categories and hospitalizations being recorded for each elderly resident, were collected.   19 
 20 
Cross-sectional dataset 21 
Trained pharmacists interviewed all participants by means of a structured questionnaire 22 
on medications use (within the week which preceded the enrolment), socio-23 
demographic information (i.e., years of education, marital status) and lifestyle habits 24 
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(i.e., nutrition, alcohol use and smoking), while six physicians (either geriatricians or 1 
clinical pharmacologists) performed the multidimensional assessment and measured the 2 
BP.  3 
Disability was evaluated with both Instrumental and Basic Activities of Daily 4 
Living (IADL and BADL) [22]. Cognitive impairment, depressive or anxiety symptoms 5 
were assessed by the Mini Mental State Examination (MMSE) [23] and the Geriatric 6 
Depression Scale (GDS) [24].  7 
Blood pressure was measured twice in each arm with the patients in the supine 8 
position, after having rested for at least 10 minutes in a quiet room at a comfortable 9 
temperature. A cuff larger than the standard was used when arm circumference 10 
exceeded 32 cm. The three sets of two BP measures were averaged, and the mean 11 
values were considered as the reference systolic and diastolic BP [25].  12 
To evaluate Orthostatic Hypotension (OH), BP was also measured on standing 13 
from sitting or supine position according to a time interval of 1, 3 and 5 minutes of 14 
standing [26]. 15 
Finally, all subjects were required to report previous diagnoses they might have 16 
received from a pre-specified list of conditions by answering the question, ‘‘Has your 17 
doctor ever told you have…?’’ [27]. All CV diseases being collected by means of 18 
claims data were purposely recollected together with asthma, chronic bronchitis, liver 19 
diseases, peptic ulcer and cancer [28].  20 
 21 
Representativeness 22 
To verify the representativeness of the “Fiesole Misurata” study database, the following 23 
estimates were computed: 24 
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• prevalence of CV diseases;  1 
• prevalence of geriatric-related assessments, based on the standard cut-off points 2 
(i.e., BADL ≥1, MMSE≤21, GDS ≥6); 3 
• distribution of co-morbidities (i.e., Silver Code scale) [28] and concomitant 4 
medications (i.e., count of ATC classes);  5 
• prevalence of AHTs use among individuals with self-reported and diagnosed 6 
hypertension; 7 
• distribution of adherence levels to AHTs.   8 
 9 
Data analysis  10 
Percentages, mean values, and related 95% Confidence Intervals (CIs) were computed 11 
for categorical and continuous variables,.     12 
Proportions of socio-demographic, lifestyle and clinical features (i.e., geriatric 13 
assessments, comorbidity and overall medication use) were calculated by using  the  14 
2,228 residents and 385 survey participants as denominators for claims and cross-15 
sectional dataset, respectively.     16 
Blood pressure categories were defined by following the official guidelines [9, 17 
29-31]. Subjects were diagnosed according to different thresholds, and classified as 18 
having ‘Optimal’ (<120/<80 mmHg), ‘Normal’ (120-129/80-84 mmHg), ‘High normal’ 19 
(130-139/80-85 mmHg), ‘Hypertension, grade I’ (140-149/90-99 mmHg), 20 
‘Hypertension, grade II-III’ (>160/>100 mmHg), ‘Isolate systolic’ (>140/<90 mmHg) 21 
BP. The OH was defined as a decrease of at least 20 mm Hg in systolic BP (or systolic 22 
BP less than 90 mm Hg) or a decrease of at least 10 mm Hg in diastolic BP when 23 
changing from clinostatism to orthostatism [26].  24 
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Basic Activities of Daily Living and IADL were registered as continuous and 1 
categorical variables. The categorization was obtained by grouping subjects who had 2 
lost more than 1 functional autonomy against those who had not lost any of them. 3 
According to the literature, MMSE score, which decreases with cognitive impairment, 4 
and the GDS score, which increases with depression symptoms, were dichotomized at 5 
21 [23] and 6 [24], respectively.  The Silver Code was adopted to estimate to the burden 6 
of co-morbidity: as per Di Bari and co-workers [28] population was stratified into four 7 
prognostic groups based on the individual score (0–3, 4–6, 7–10, and ≥11).  8 
With regard to medications, at first, the distribution of AHT classes and other 9 
CV medications were computed as proportional values in both claims and cross-10 
sectional dataset. Consequently, using the claims data, Drug Daily Dosages 11 
(DDDs/1000 inhabitants/day) being prescribed for AHTs as a class and stratified by any 12 
single chemical group, were calculated over two years (1 May, 2008- 31 April, 2009 13 
versus 1 May, 2009-31 April, 2010). Then, the degree of adherence to AHT was 14 
calculated, in claims dataset, among the incident users of AHT. As such, all subjects 15 
receiving the first prescription (cohort entry) of AHT from the 1st June 2008 to the 31st 16 
February 2010 were identified (i.e., excluding patients prescribed AHTs before the 17 
cohort entry). In addition, those with less than 180 days of follow-up after the first 18 
prescription were excluded. The adherence was computed as Proportion of Days 19 
Covered (PDC), calculated by dividing the cumulative days of AHTs use by the length 20 
of follow-up. The number of days supplied from each prescription was calculated by 21 
dividing the total amount of active drug in each prescription by the recommended 22 
DDDs. All dispensed prescriptions were considered interchangeable. Thus, all overlaps 23 
between two or more AHTs prescriptions were subtracted by the total cumulative days 24 
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of use. When a gap between two treatment periods was  ≤90 days, subjects were still 1 
considered being on therapy. Therefore, progressively growing adherence was 2 
categorized as low with a PDC value <40% , intermediate and high with PDC values 3 
40-79% and ≥80%, respectively [10, 32]. According to the subject-specific follow-up, 4 
PDC strata were computed at intervals of 6, 12, 18 and 24 months.  5 
Finally, subjects who had at least two prescriptions of AHTs, according to their 6 
self-reported and diagnosed hypertension, were categorized as ‘self-reported’, ‘mild-7 
degree’ (130-139/81-89 mmHg)’ and ‘severe-degree’ (≥140/≥90 mmHg) hypertensive 8 
subjects. 9 
 10 
 11 
RESULTS 12 
The claim and cross-sectional dataset consisted of 2,228 and 385 older individuals, 13 
respectively. In both datasets, most individuals were females. In the claim dataset, the 14 
highest proportion of subjects were less than 70 years, in the cross-sectional dataset the 15 
highest proportion of subjects were 70-74 years (Table 1). In the claim dataset, females 16 
were older than males, while in the cross-sectional one, age categories were equally 17 
distributed between genders.  18 
Drugs were purchased in 269 different pharmacies, but three of them covered 19 
84% of all dispensed medications. Moreover, patients were assisted by a total of 128 20 
general practitioners with eight of them covering 82% of them.  21 
 In the claim dataset, the burden of comorbidity was lower in females then in 22 
males, especially for the highest sub-category of the Silver Code (8.4% versus 15.3%, 23 
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Table 2). These results were in line with the number of hospitalizations per subject, the 1 
number of concomitant medications and the prevalence of hospitalizations due to CV 2 
diseases. Among the latters, ischemic cardiomyopathy was 3-fold higher in males than 3 
in females, and the corresponding CIs were not overlapped. This picture was maintained 4 
among AHTs users, where males outnumbered females for any medication class with 5 
the exception of diuretics, central inhibitors and fixed combinations (Table 3).  6 
As a whole, the prescribed DDDs were higher in 2009 as compared to 2008 for 7 
all AHTs, with the exception of ACE inhibitors (Figure 1).  8 
Two-hundred-and-thirty individuals  (10.3%of 2,228) constituted the AHT 9 
inception dataset. In detail 63.5% were highly adherent to AHTs over the first six 10 
months of their treatment, while 14.3% and 22.2% showed intermediate and low levels, 11 
respectively (Figure 2). The percentage of the high adherent subjects decreased with 12 
time reaching 31.2% at the 24th month.    13 
The prevalence of self-reported and diagnosed hypertension was lower in 14 
females than in males (Table 4). In contrast, OH was more frequent among females. 15 
Subjects who had BP equal to or over than 140/90 mmHg underreported to suffer from 16 
hypertension. Specifically, 36/86 (41.9%) females and 28/68 (41.2%) males wrongly 17 
reported to be normotensive or mild-hypertensive, respectively (data not shown). With 18 
the exception of dyslipidaemia, all CV diseases appeared more common in males, as 19 
well as the reduction of cognitive functions (Table 4). On the contrary, females were 20 
more functionally impaired and more depressed than men. Taken as whole, disability, 21 
cognitive status and depression degree accordingly increased with the participants’ age.  22 
The prevalent users of AHTs were slightly higher among females, almost for all 23 
medication classes. Only sartans and peripheral alpha blockers were more frequently 24 
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prescribed in males (Table 5). Diuretics were the most reported medications, followed 1 
by ACE inhibitors and sartans (47.0%, 45.3%, and 33.6%, respectively).  2 
Generally, almost the 70% of subjects with clinically assessed mild or severe 3 
hypertension were pharmacologically treated (Figure 3). 4 
 5 
DISCUSSION 6 
This paper describes the methodology with which the representativeness of the “Fiesole 7 
Misurata” database was evaluated. To our knowledge, this is the first pharmaco-8 
epidemiological tool focused on older subjects which comprises both administrative and 9 
clinical information.  10 
In the claim dataset, the distribution of age categories was acceptably 11 
representative of the Italian older population, although the prevalence of older people 12 
was slightly lower than that reported by the official statistics (16% in Fiesole versus 18-13 
20% in Italy)  [15, 33], and about 25% aged more than 80 years. Concerning the cross-14 
sectional dataset, the lower number of younger participants was likely due to self-15 
selection of subjects after the proposal of participation.. Indeed, the fact that subjects 16 
were instructed about the study topic could have fostered the participation of elders 17 
aged more than 70, who knew better their CV conditions and were featured by an higher 18 
burden of comorbidity [18, 27, 28, 34].    19 
Also the prevalence of CV diseases was in line with previous results. As shown 20 
by “Progetto Cuore” (a comprehensive study on epidemiology of CV diseases in Italy) 21 
[8, 35, 36], and in keeping with what was found in other international contexts [3, 5, 6], 22 
these diseases are more common in males. On the other hand, the comparison between 23 
claim and cross-sectional dataset showed some differences. The fact that acute events 24 
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(i.e., ischemic cardiomyopathy, stroke, certain arrhythmias) were more frequently 1 
reported  in the cross-sectional dataset is likely due to the cumulative effect of the self-2 
reported diagnoses. In fact, while they can cover the entire life-time period of each 3 
participant, the clinical history in claim datasets was limited to the previous two-year 4 
period. , Consistently, our cross-sectional estimates agreed with those obtained by Landi 5 
and coworkers [18] who  enrolled patients  with a similar  design Also heart failure was 6 
more prevalent in the cross-sectional dataset. The discrepancy  with claim dataset is 7 
likely due to the aforementioned reasons along with the chronic course of this disease 8 
[37]. In fact,  hospitalizations due to exacerbations of heart failure could occur in a 9 
period longer than that we were able to analyse.  10 
According to “Fiesole Misurata” study, 27.0% of subjects were classified as 11 
functionally impaired. These estimates were in keeping with similar surveys [38, 39]. 12 
Accordingly, the prevalence of cognitive status [40], depression [41], OH [26], burden 13 
of comorbidities [18, 34] and co-medications [18, 42-45] were consistent with previous 14 
estimates.  15 
As hypertension was considered, the self-reporting diagnoses underestimated  16 
(almost 10% lower) the prevalence of hypertension when compared with the actual BP 17 
measurement during the study. Specifically, more than one-third of participants 18 
misclassified their BP status; this is in line with the fact that elderly individuals usually 19 
underestimate their levels of BP, even if patients’ unawareness of  hypertension is 20 
recently decreased in western countries [29]. Furthermore, while the percentage of 21 
subjects with severe hypertension was higher than 65%, the adherence to AHTs sensibly 22 
decreased during the two years after the first prescription. In any case, more than 20% 23 
of individuals with severe hypertension did not receive any prescription, and more than 24 
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30% of the incident users were non-adherent in the first six months of follow-up. These 1 
findings demonstrate that the poor AHTs-taking behaviour is quantitatively similar to 2 
that reported in the middle-aged population [10, 32]. These results were further 3 
strengthened by the fact that the prevalence of each single drug category and the 4 
prescribed DDDs agreed with the official prescription reports [46, 47] and previous 5 
investigations [48].         6 
From a public health perspective, the “Fiesole Misurata” study could be 7 
important in several ways. First of all, it offers a comprehensive picture of a 8 
community-based older population in terms of health claim information and clinical 9 
features. Furthermore, the quantification of AHTs non-adherence, as well as the 10 
measurement of OH, have not been previously reported in an Italian elderly population.       11 
Certainly, the present study has limitations. Firstly, the cross-sectional sample 12 
has not been randomly selected and it could be therefore affected by selection bias. 13 
However, given that all estimates concerning both diseases and medications use were 14 
consistent with prior studies, the driven selection of certain patients’ categories should 15 
have been minimized. Secondly, some diagnoses coded in claims databases could be 16 
underestimated because they are limited to hospital discharge charts. Nevertheless, 17 
given that elders are more frequently hospitalized than younger adults, we can assume 18 
that underestimation of cardiovascular and other specific diseases (e.g., COPD) is 19 
generally negligible in this age category. Finally, claims databases do not comprise the 20 
indication of drug use. As a consequence, subjects cannot be differentiated between 21 
those who suffer from hypertension and/or heart failure or other conditions.  However, 22 
the non-adherent behaviour to AHTs equally affects all  CV illnesses.  23 
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Despite these limitations, the present study does not undermine the observed 1 
values, particularly considering few Randomized Clinical Trials (RCTs) are conducted 2 
in elderly patients, and RCTs often fail to appropriately evaluate the issues related to 3 
medications-non-adherence [2]. In particular, differences in drug tolerability, dosing 4 
variability, and patient perceptions of the disease are observational (i.e., “real-world”) 5 
variables which can remarkably influence the adherence to AHTs. For this reason, 6 
appropriate strategies to correct these factors should be implemented.  7 
Given that the clinical characteristics of older people residents in Fiesole appear 8 
consistent with those of the Italian older population, it is our opinion that further 9 
strategies aimed at improving the adherence to AHTs can be implemented and 10 
epidemiologically verified by adopting  “Fiesole Misurata” study database. 11 
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Figure Legends 
 
Figure 1. Use of antihypertensives broken down by the period of use in the claim dataset 
(DDD/1000 inhabitants/die). ACE: Angiotensin-Converting Enzyme; CCBs : Calcium 
Channel Blockers; DDDs: Drug Daily Dosages 
Figure 2. Degree of adherence among new users of antihypertensives in the AHT dataset.  
AHT: AntiHyperTensive 
Figure 3. Degree of treatment among self-reported and diagnosed hypertensive subjects in the 
cross-sectional dataset.  Mild hypertensive subjects: blood pressure 130-139/81-89 mmHg; 
Severe hypertensive subjects: blood pressure ≥140/≥90 mmHg; Treated: at least two 
antihypertensive prescriptions. 
 
21 
 
Figure 1. Use of antihypertensives broken down by the period of use in the claim dataset 
(DDD/1000 inhabitants/die). ACE: Angiotensin-Converting Enzyme; CCBs : Calcium Channel 
Blockers; DDDs: Drug Daily Dosages 
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Figure 2. Degree of adherence among new users of antihypertensives in the AHT dataset.   
AHT: AntiHyperTensive 
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Figure 3. Degree of treatment among self-reported and diagnosed hypertensive subjects in the 
cross-sectional dataset.  Mild hypertensive subjects: blood pressure 130-139/81-89 mmHg; 
Severe hypertensive subjects: blood pressure ≥140/≥90 mmHg; Treated: at least two 
antihypertensive prescriptions. 
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Table 1. Distribution of older subjects’ demographics in the claim (n=2,228) and the cross-
sectional (n=385) dataset. 
 
Number 
Percentage (95% CI) 
Overall Females Males 
 
Claims dataset 
   
 
No. of residents 
 
2,228 
 
1,274 
 
954 
 
Age (years) 
   
<70 
743  
33.4 (31.4-35.3) 
395  
31.0 (28.4-33.6) 
348  
36.4 (33.4-39.6) 
70-74 
515  
23.1 (21.4-24.9) 
295 
23.2 (20.9-25.6) 
220 
23.1 (20.4-25.9) 
75-79 
413 
18.5 (16.9-20.2) 
226  
17.7 (15.7-19.9) 
187 
19.6 (17.1-22.2) 
80-84 
308 
13.8 (12.4-15-3) 
186 
14.6 (12.7-16.6) 
122 
12.8 (10.7-15.1) 
>84 
249  
11.2 (9.9-12.6) 
172 
13.5 (11.7-15.5) 
77 
8.1 (6.4-10.0) 
 
Cross-sectional dataset 
   
 
No. of participants 
 
385 
 
220 
 
165 
 
Age (years) 
   
<70 
76  
19.7 (15.9-2.1) 
41 
18.6 (13.7-24.4) 
35 
21.2 (15.2-28.2) 
70-74 
92  
23.9 (19.1-28.5) 
63 
28.7 (22.8-35.1) 
29 
17.6 (12.1-24.3) 
75-79 
83  
21.6 (17.6-26.0) 
46 
20.9 (15.7-26.9) 
37 
22.4 (16.3-29.6) 
80-84 
74 
19.2 (15.4-23.5) 
39 
17.7 (12.9-23.4) 
35 
21.2 (15.2-28.2) 
>84 
60  
15.6 (12.1-19.6) 
31 
14.1 (9.8-19.4) 
29 
17.6 (12.1-24.3) 
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Table 2. Distribution of residents’ clinical features in the claims dataset (n=2,228). 
 
Number 
Percentage (95% CI) 
Overall 
(N=2,228) 
Females 
(N=1,274) 
Males 
(N=954) 
 
Silver Code categories 
   
0-3 
1,459 
65.5 (63.4-67.4) 
912 
71.6 (68.9-74.0) 
547 
57.3 (54.1-60.5) 
4-6 
364 
16.3 (14.9-18.0) 
138 
10.8 (9.2-12.7) 
226 
23.7 (21.0-26.5) 
7-10 
152 
6.8 (5.8-7.9) 
117 
9.2 (7.6-10.9) 
35 
3.7 (2.6-5.1) 
≥11 
253 
11.4 (10.1-12.7) 
107 
8.4 (6.9-10.0) 
146 
15.3 (13.1-17.7) 
Hospitalizations/Subjects a 
 
1,271/2,228 
0.6 
 
653/1,274 
0.5 
 
618/954 
0.6 
Number of subjects with 
hospital data 
663 
29.8 (27.9-31.7) 
342  
26.8 (24.4-29.4) 
321  
33.6 (30.6-36.4) 
 
Prevalent hospitalizations 
   
Diabetes  
(or antidiabetics: ATC A10*) 
313 
14.0 (12.6-15.6) 
152 
11.9 (10.2-13.8) 
161 
16.7 (14.5-1.94) 
Ischemic cardiomyopathy 
83 
3.7 (3.0-4.6) 
26 
2.0 (1.3-3.0) 
57 
6.0 (4.6-7.7) 
Heart failure 
67 
3.0 (2.3-3.8) 
33 
2.6 (1.8-3.6) 
34 
3.6 (2.5-4.9) 
Haemorrhagic and ischemic 
stroke 
72 
3.2 (2.5-4.0) 
38 
3.0 (2.1-4.1) 
34 
3.6 (2.5-4.9) 
Cardiac Arrhythmia 
77 
3.5 (2.7-4.3) 
37 
2.9 (2.1-4.0) 
40 
4.2 (3.0-5.7) 
 
Number of co-prescribed drugs b 
  
mean (±SD) 5.2 (± 5.1) 5.8 (± 4.6) 5.6 (± 5.5) 
 
Number of medications 
   
0 
1,377 
61.8 (59.7-63.8) 
824 
64.7 (62.0-67.3) 
553 
58.0 (54.8-61.1) 
1-4  
578 
26.0 (24.1-27.8) 
320 
25.1 (22.7-27.6) 
258 
27.0 (24.2-30.0) 
≥5  
273 
12.2 (10.9-13.7) 
130 
10.2 (8.6-12.0) 
143 
15.0 (12.8-17.4) 
    
a ratio  
b any single ATC among medication users 
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Table 3. Distribution of resident’s use of antihypertensives and other CV medications in the 
claim dataset (n=2,228). 
 
Number 
Percentage (95% CI) 
Overall 
(N=2,228) 
Females 
(N=1,274) 
Males 
(N=954) 
 
Prevalent users of antihypertensives a 
  
Overall 
1,507        
67.6 (65.6-69.6) 
869 
68.2 (65.6-70.8) 
638 
66.9 (63.8-69.8) 
Age strata (years)    
<70 
743 
54.2 (50.6-57.9) 
395 
54.2 (49.1-59.2) 
348 
54.3 (48.9-59.6) 
70-74 
515 
68.3 (64.1-72.3) 
295 
65.1 (59.3-70.5) 
220 
72.7 (66.3-78.5) 
75-79 
413 
74.8 (70.3-78.9) 
226  
76.1 (70.0-81.5) 
187 
73.3 (66.3-79.5) 
80-84 
308 
76.9 (71.8-81.5) 
186 
80.6 (74.2-86.1) 
122 
71.3 (62.4-79.1) 
>84 
249 
82.7 (77.4-87.2) 
172 
82.0 (75.4-87.4) 
77 
84.4 (74.4-91.7) 
Medication class a    
ACE inhibitors (C09A*) 
657 
43.6 (41.1-46.1) 
352 
40.5 (37.2-43.8) 
305 
47.8 (43.9-51.8) 
Diuretics (C03*) 
536 
35.6 (33.1-38.0) 
324  
37.3 (34.0-40.6) 
212  
33.2 (29.6-37.0) 
Sartans (C09C*) 
371  
24.6 (22.5-26.9) 
204  
23.5 (20.7-26.4) 
167  
26.2 (22.8-29.8) 
Beta blockers (C07A*; 
C07EA*) 
454  
30.1 (27.8-32.5) 
248  
28.5 (25.5-31.7) 
206  
32.3 (28.7-36.1) 
CCBs – DHP (C08CA*) 
482  
32.0 (29.6-34.4) 
271  
31.2 (28.1-34.4) 
211  
33.1 (29.4-36.9) 
Central inhibitors (C02A*) 
26 
1.7 (1.1-2.5) 
16  
1.8 (1.0-3.0) 
10  
1.6 (0.7-2.9) 
Alfa blockers, peripheral 
(C02C*) 
148 
9.8 (8.4-11.4) 
59 
6.8 (5.2-8.7) 
89  
13.9 (11.3-16.9) 
CCBs - non DHP 
(C08CX01; C08D*; 
C08E*) 
100 
6.6 (5.4-8.0) 
51  
5.9 (4.4-7.6) 
49 
7.7 (5.7-10.0) 
Beta blockers and diuretics 
(C07B*; C07C) 
30 
2.0 (1.3-2.8) 
20  
2.3 (1.4-3.5) 
10 
1.6 (0.7-2.8) 
ACE inhibitors and 
Diuretics (C09B*) 
408 
27.1 (24.8-29.4) 
238 
27.4 (24.4-30.5) 
170 
26.7 (23.2-30.2) 
Diuretics and Sartans  
342 
22.7 (20.6-24.9) 
210 
24.2 (21.3-27.1) 
132 
20.7 (17.6-24.0) 
Table 3. continues 
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Table 3. continued  
 
Number 
Percentage (95% CI) 
Overall 
(N=2,228) 
Females 
(N=1,274) 
Males 
(N=954) 
 
Prevalent users of other CV medications 
  
Antithrombotics (B01A*)  1134 
50.9 (48.8-53.0) 
611 
48.0 (45.2-50.7) 
523 
54.8 (51.7-
58.0) 
Antiarrhythmics (C01B*)  636 
28.5 (26.7-30.4) 
336 
26.4 (24.0-28.8) 
300 
31.4 (28.5-
34.4) 
Digitalis (C01A*)  131 
5.9 (4.9-6.9) 
66 
5.2 (4.0-6.4) 
65 
6.8 (5.2-8.4) 
Lipid lowering (C10*) 540 
24.2 (22.5-26.0) 
270 
21.2 (18.9-23.4) 
270 
28.3 (25.4-
31.2) 
    
ACE: Angiotensin-Converting Enzyme   
CV: CardioVascular 
CCBs : Calcium Channel Blockers 
DHP: dihydropiridinic   
a denominator: prevalent users of antihypertensive medications (n=1,507 ) 
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Table 4. Distribution of subject’s clinical features in the cross-sectional dataset (n=385). 
 
Number 
Percentage (95% CI) 
Overall 
(N=385) 
Females 
(N=220) 
Males 
(N=165) 
 
BP (mmHg) 
   
Optimal: <120/<80  
71 
18.4 (14.7-22.7) 
43 
19.5 (14.5-25.4) 
28 
17.0 (11.6-23.6) 
Normal: 120-129/80-84  
114 
29.6 (25.1-34.4) 
69 
31.4 (25.3-37.9) 
45 
27.3 (20.6-34.7) 
High normal: 130-139/80-85  
32 
8.3 (5.7-11.5) 
16 
7.3 (4.2-11.5) 
16 
9.7 (5.6-15.3) 
Hypertension, grade I: 140-
159/90-99  
43 
11.2 (8.2-14.7) 
22 
10.0 (6.3-14.7) 
21 
12.7 (8.0-18.8) 
Hypertension, grade II-III: 
>160/>100  
23 
6.0 (3.8-8.8) 
13 
5.9 (3.2-9.9) 
10 
6.1 (2.9-10.9) 
Isolate Systolic: >140/<90  
88 
22.9 (18.8-27.4) 
51 
23.2 (17.8-29.3) 
37 
22.4 (16.3-29.6) 
missing 
14 
3.6 (0.2-6.0) 
6 
2.7 (0.1-5.8) 
8 
4.8 (2.1-9.3) 
 
Orthostatic Hypotension a 
   
No 
306  
79.5 (75.1-85.3) 
174 
79.1 (73.1-84.3) 
132 
80.0 (73.1-85.8) 
Yes 
48 
12.5 (9.3-16.2) 
31 
14.1 (9.8-19.4) 
17 
10.3 (6.1-16.0) 
missing 
31 
8.0 (5.5-11.2) 
15 
6.8 (3.8-11.0) 
16 
9.7 (5.6-15.3) 
 
Cardiovascular disease 
   
Dyslipidaemia 
141 
36.6 (31.8-41.6) 
96  
43.6 (37.0-50.2) 
45 
27.3 (20.4-34.1) 
Diabetes (or use of antidiabetic 
drugs) 
52 
13.5 (10.1-16.9) 
28  
12.7 (8.3-17.2) 
24  
14.5 (9.1-20.0) 
Ischemic cardiomyopathy 
43  
11.2 (8.0-14.3) 
20  
9.1 (5.3-12.9) 
23 
13.9 (8.6-19.3) 
Heart failure 
26  
6.7 (4.2-9.3) 
14  
6.4 (3.1-9.6) 
12 
7.3 (3.3-11.3) 
Haemorrhagic and ischemic 
stroke 
27  
7.1 (4.4-9.6) 
15  
6.8 (3.5-10.2) 
12 
7.3 (3.3-11.3) 
Self-reported hypertension 
222  
57.7 (52.7-62.6) 
125  
56.8 (50.2-63.4) 
97 
58.8 (51.2-66.4) 
Table 4. continues 
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Table 4. continued 
 
Number 
Percentage (95% CI) 
Overall 
(N=385) 
Females 
(N=220) 
Males 
(N=165) 
 
Functional status (lost) 
   
BADL, mean (± SD) 
0.6 (±1.3) 
(0.5-0.7) 
0.6 (±1.4) 
(0.5-0.8) 
0.5 (±1.3) 
(0.3-0.7) 
IADL, mean (± SD) 
0.7 (±1.7) 
(0.5-0.8) 
0.8 (±1.8) 
(0.5-1.0) 
0.5 (±1.5) 
(0.3-0.8) 
BADL ≥1    
Overall 
104 
27.0 (22.6-31.7) 
66 
30.0 (24.0-36.5) 
38 
 23.0 (16.8-30.2) 
Age strata    
<70 
3 
4.1 (0.9-11.5) 
2 
5.3 (0.6-17.7) 
1 
2.9 (0.7-14.9) 
70-74 
22 
24.2 (15.8-34.3) 
15 
23.8 (14.0-36.2) 
7  
25.0 (10.7-44.9) 
75-79 
26 
31.3 (21.6-42.4) 
17  
37.0 (23.2-52.4) 
9 
24.3 (11.8-41.2) 
80-84 
25  
34.2 (23.5-46.3) 
16  
41.0 (25.6-57.9) 
9 
 26.9 (12.9-44.4) 
>84 
28  
53.8 (39.5-67.8) 
16 
57.1 (37.2-75.5) 
12 
 50.0 (29.1-70.9) 
missing 
13  
3.4 (1.8-5.7) 
6 
2.7 (1.0-5.8) 
7 
4.2 (1.7-8.5) 
 
Cognitive status 
   
MMSE, mean (± SD) 
26.6 (±3.6) 
(26.3-27.0) 
26.7 (±3.6) 
(26.2-27.2) 
26.6 (±3.6) 
(26.0-27.2) 
MMSE ≤21    
Overall 
27 
7.0 (4.7-10.0) 
11  
5.0 (2.5-8.8) 
16  
9.7 (5.6-15.3) 
Age strata    
<70 
1  
1.3 (0.03-7.3) 
1 
2.6 (0.07-13.5) 
- 
70-74 
2  
2.2 (0.3-7.9) 
1  
1.6 (0.04-8.8) 
1  
3.6 (0.09-18.3) 
75-79 
3  
3.6 (0.7-10.2) 
3 
6.5 (1.4-17.9) 
- 
80-84 
4  
5.4 (1.5-13.3) 
1 
 2.6 (0.07-13.5) 
3 
8.6 (1.8-23.0) 
>84 
17 
30.9 (19.1-44.8) 
5 
17.9 (6.1-36.9) 
12 
44.4 (25.5-64.7) 
missing 
10 
2.6 (1.2-4.7) 
7 
3.2 (1.3-6.4) 
3 
1.8 (0.4-5.2) 
Table 4. continues 
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Table 4. continued 
 
Number 
Percentage (95% CI) 
Overall 
(N=385) 
Females 
(N=220) 
Males 
(N=165) 
Depression    
GDS, mean (± SD) 
3.3 (±2.8) 
(3.0-3.6) 
3.9 (±2.9) 
(3.5-4.3) 
2.5 (±2.5) 
(2.1-2.9) 
GDS ≥6    
Overall 
77 
20.0 (16.1-24.3) 
54 
24.5 (19.0-30.8) 
23 
13.9 (9.0-20.2) 
Age strata    
<70 
5 
6.8 (2.2-15.1) 
4 
10.3 (2.9-24.2) 
1 
2.9 (0.07-14.9) 
70-74 
21 
23.6 (15.2-33.8) 
15 
24.6 (14.5-37.3) 
6 
21.4 (8.3-40.9) 
75-79 
18 
21.7 (13.4-32.1) 
12 
26.1 (14.3-41.1) 
6 
16.2 (6.2-32.0) 
80-84 
17 
23.3 (14.2-34.6) 
12 
31.6 (17.5-48.6) 
5 
14.3 (4.8-30.3) 
>84 
16 
30.8 (18.7-45.1) 
11 
42.3 (23.3-63.1) 
5 
19.2 (6.5-39.3) 
missing 
14 
3.6 (2.0-6.0) 
10 
4.5(2.2-8.2) 
4 
2.4 (0.7-6.1) 
    
BADL: Basic Activity of Daily Living 
BP: Blood Pressure 
GDS: Geriatric Depression Scale  
IADL: Instrumental Activity of Daily Living  
MMSE: Mini Mental State Examination 
SD: standard deviation 
a defined as a decrease of at least 20 mm Hg in systolic BP (or systolic BP less than 90 mm 
Hg) or a decrease of at least 10 mm Hg in diastolic BP when changing from clinostatism to 
orthostatism. 
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Table 5. Distribution of subjects’ use of antihypertensives in the cross-sectional dataset 
(n=385). 
 
Number 
Percentage (95% CI) 
Overall 
(N=385) 
Females 
(N=220) 
Males 
(N=165) 
 
Prevalent users of antihypertensives a 
  
Overall 
247 
64.2 (59.1-68.9) 
143 
65.0 (58.3-71.3) 
104 
63.0 (55.2-70.4) 
Age strata (years)    
<70 
41 
54.0 (42.1-65.4) 
23 
56.1 (39.7-71.5) 
18 
51.4 (34.0-68.6) 
70-74 
55 
59.8 (49.0-69.9) 
35 
55.6 (42.5-68.1) 
20 
69.0 (49.2-84.7) 
75-79 
59 
71.1 (60.1-80.5) 
31 
67.4 (52.0-80.5) 
28 
75.7 (58.8-88.2) 
80-84 
52 
70.3 (58.5-80.3) 
28 
71.8 (55.1-85.0) 
24 
68.6 (50.7-83.1) 
>84 
40 
66.7 (53.3-78.3) 
26 
83.9 (66.3-94.5) 
14 
48.3 (29.4-67.5) 
Medication class a    
ACE inhibitors  
112 
45.3 (39.0-51.8) 
66 
46.1 (37.8-54.7) 
46 
44.2 (34.5-54.3) 
Diuretics  
116 
47.0 (40.6-53.4) 
69 
48.2 (39.8-56.7) 
47 
45.2 (35.4-55.2) 
Sartans  
83 
33.6 (27.7-39.9) 
46 
32.2 (24.6-40.5) 
37 
35.6 (26.4-45.6) 
Beta blockers  
62 
25.1 (19.8-31.0) 
43 
30.1 (22.7-38.2) 
19 
18.3 (11.4-27.0) 
CCBs - DHP 
51 
20.7 (15.8-26.2) 
32 
22.4 (15.8-30.1) 
19 
18.3 (11.4-27.0) 
Central inhibitors  
45 
18.2 (13.6-23.6) 
33 
23.1 (16.4-30.8) 
12 
11.5 (6.1-19.3) 
Alfa blockers, peripheral  
35 
14.2 (10.1-19.1) 
8 
5.6 (2.4-10.7) 
27 
26.0 (17.9-25.5) 
CCBs - non DHP  
7 
2.8 (1.1-5.7) 
5 
3.5 (1.1-8.0) 
2 
1.9 (0.2-6.8) 
 
Prevalent users of other CV medications 
  
Antiaggregants 
130 
33.8 (29.0-38.7) 
72 
32.7 (26.6-39.4) 
58 
35.1 (27.9-43.0) 
Statins 
79 
20.5 (16.6-24.9) 
53 
24.1 (10.6-30.3) 
26 
17.8 (10.6-22-2) 
    
ACE: Angiotensin-Converting Enzyme   
CV: CardioVascular 
CCBs : Calcium Channel Blockers 
DHP: dihydropiridinic   
a denominator: prevalent users of antihypertensive medications (n=247) 
